As per a new classification system of cancer that is based on molecular subtypes of opposed to origin of disease, the patients’ therapeutic options can be improved.
This new study was published in Cell on the 7th of August. It was reported by the University of California, Santa Cruz that as per this study, reclassification of 1 out of every 10 cancers was done.
The classification of only 10 percent was done differently, but it matters a lot if one is among those patients, stated a professor of biomolecular engineering at UC Santa Cruz and senior author, Josh Stuart.
The molecular data from 1000s of patients with twelve different kinds of cancer, was analyzed comprehensively.
With this study, the most diverse and comprehensive collection of tumors that were ever analyzed with these methods, is represented. After the analysis of data from 6 different platforms, division of tumors was done into clusters.
Then, there was division of cancer into 11 major subtypes, out of which 5 were based on tissue of origin. Some other were split into some specific groups. For example, bladder cancer was split into 7 clusters and many of them fell in 3 subtypes.
If the survival rates are looked upon, bladder cancers that are clustered with other types of tumor had a worse prognosis. Stuart stated that this wasn’t just an academic exercise.
The same subtypes were identified by all 6 platforms for molecular analysis. Researchers get the confidence that tumors can be classified by different types of data.
Now, the tumor of the patient can be classified on the basis of gene expression data, just based on mutation data. Stuart further said that with a molecular map like this, patients can get into the right clinical trial. There is a need of further research for validating the findings.